Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-099409
Filing Date
2025-07-29
Accepted
2025-07-29 09:16:10
Documents
87
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q alks-20250630.htm   iXBRL 10-Q 3356420
2 EX-31.1 alks-ex31_1.htm EX-31.1 19279
3 EX-31.2 alks-ex31_2.htm EX-31.2 19294
4 EX-32.1 alks-ex32_1.htm EX-32.1 24397
5 GRAPHIC img78443806_0.jpg GRAPHIC 13021
6 GRAPHIC img78443806_1.jpg GRAPHIC 134869
7 GRAPHIC img78443806_2.jpg GRAPHIC 140207
8 GRAPHIC img78443806_3.jpg GRAPHIC 66302
  Complete submission text file 0000950170-25-099409.txt   13551161

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alks-20250630.xsd EX-101.SCH 1337020
90 EXTRACTED XBRL INSTANCE DOCUMENT alks-20250630_htm.xml XML 2853205
Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35299 | Film No.: 251157884
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)